具有胶质母细胞瘤的患者预后不良，并且没有循环预测或预后生物标志物。循环前胃泌素hPG80是一种在患有各种癌症的患者血液中存在的促肿瘤肽，已被证明具有预后价值。我们评估了手术后患有异柠檬酸脱氢酶野生型胶质母细胞瘤的患者血浆hPG80的预后价值。进行了一项多中心回顾性研究，对接受标准放化疗治疗的胶质母细胞瘤患者进行了研究。使用ELISA DxPG80.lab试剂盒（Biodena Care, Montpellier, France）对术后采集的EDTA血浆样本中的hPG80水平进行测量，试剂盒的检测阈值为1.2 pM。评估了术后hPG80血浆水平与其他已知预后因素结合对患者无进展生存期（PFS）和总生存期（OS）的关系。共有69名患者可评估。分别对于囊肿活检（B）、部分切除（PR）和完全切除（CR），22名、25名和22名患者的血浆样本进行了采集。在中位浓度为5.37 pM（四分位范围0.00-13.90 pM）的情况下，检测到48名（70%）患者的hPG80（hPG80+）。CR与较低的hPG80水平显著相关：其中位数值为0.7 pM，而PR为9.1 pM（P = 0.02），B为8.3 pM（P = 0.004）。hPG80检测率也显著较低：CR为50%与PR为72%，B为86%（P = 0.005）。中位随访时间为39个月[22.4个月-未达到]。术后检测到hPG80与PFS（6.4个月对9.4个月，P = 0.13）和OS（14.5个月对20.9个月，P = 0.11）显著较短相关。多变量分析中，hPG80是OS的预后因子（P = 0.034）。循环hPG80可作为接受放化疗治疗的胶质母细胞瘤患者手术后的新的预后生物标志物。版权所有 © 2023 作者。由Elsevier Ltd.发表。保留所有权利。

Patients with glioblastomas have a dismal prognosis, and there is no circulating predictive or prognostic biomarker. Circulating progastrin, hPG80, is a tumor-promoting peptide present in the blood of patients with various cancers that has been shown to have prognostic value. We evaluated the prognostic value of plasma hPG80 in patients with isocitrate dehydrogenase-wild type glioblastoma after surgery.A multicentric retrospective study in glioblastoma patients treated with standard radio-chemotherapy was conducted. The hPG80 levels were measured in plasma EDTA samples collected after surgery with an ELISA DxPG80.lab kit (Biodena Care, Montpellier, France), which has a detection threshold of 1.2 pM. The relationship between post-operative hPG80 plasma levels, in combination with other known prognostic factors, and patients' progression-free survival (PFS) and overall survival (OS) was evaluated.Sixty-nine patients were assessable. Plasma samples were collected after tumor biopsy (B), partial resection (PR), and complete resection (CR) for 22, 25, and 22 patients, respectively. At a median concentration of 5.37 pM (interquartile range 0.00-13.90 pM), hPG80 was detected in 48 (70%) patients (hPG80+). CR was associated with significant lower values of hPG80 levels: the median value was 0.7 versus 9.1 pM for PR (P = 0.02) and 8.3 pM for B (P = 0.004). The hPG80 detection rate was also significantly lower: 50% (CR) versus 72% (PR) versus 86% (B) (P = 0.005). The median follow-up was 39 months [22.4 months-not reached]. hPG80 post-operative detection was associated with numerically shorter PFS (6.4 versus 9.4 months, P = 0.13) and OS (14.5 versus 20.9 months, P = 0.11). In multivariate analysis, hPG80 was a prognostic factor for OS (P = 0.034).Circulating hPG80 could serve as a new prognostic biomarker after surgery in patients with glioblastoma treated with radio-chemotherapy.Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.